Feiba VH Disease Interactions
There is 1 disease interaction with Feiba VH (anti-inhibitor coagulant complex).
Anti- inhibitor coagulation (applies to Feiba VH) thrombo/hemorrhage
Major Potential Hazard, High plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation, Myocardial Infarction, Pulmonary Embolism
The use of anti- inhibitor coagulant complex is contraindicated in patients with significant signs of fibrinolysis, disseminated intravascular coagulation (DIC), and acute thrombosis or embolism including myocardial infarction. Anti- inhibitor coagulant complex contains Factor VIII inhibitor bypassing activity and prothrombin complex factors and may cause or exacerbate fibrinolysis or coagulation. If DIC or fibrinolysis occurs during treatment, the infusion should be stopped promptly and appropriate therapeutic measures initiated. Thromboembolic events may also occur during treatment, particularly following the administration of large doses and/or in patients with thrombotic risk factors. Caution is advised when administering anti- inhibitor coagulant complex to patients with an active or past history of thromboembolic disorders.
Switch to professional interaction data
Feiba VH drug interactions
There are 7 drug interactions with Feiba VH (anti-inhibitor coagulant complex).
More about Feiba VH (anti-inhibitor coagulant complex)
- Feiba VH consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- Drug class: miscellaneous coagulation modifiers
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.